MD3691692T2 - Conjugaţi medicament anticorp activabili anti-CD71 și metode de utilizare a acestora - Google Patents
Conjugaţi medicament anticorp activabili anti-CD71 și metode de utilizare a acestoraInfo
- Publication number
- MD3691692T2 MD3691692T2 MDE20200822T MDE20200822T MD3691692T2 MD 3691692 T2 MD3691692 T2 MD 3691692T2 MD E20200822 T MDE20200822 T MD E20200822T MD E20200822 T MDE20200822 T MD E20200822T MD 3691692 T2 MD3691692 T2 MD 3691692T2
- Authority
- MD
- Moldova
- Prior art keywords
- methods
- drug conjugates
- antibody drug
- activatable antibody
- activating antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Invenţia se referă în general la anticorpi activabili conjugaţi care leagă CD71 în forma lor activă şi metode de crearea a cestora şi utilizarea acestor anticorpi activabili conjugaţi anti-CD71 într-o varietate de indicaţii terapeutice, de diagnoză şi profilactice.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762572467P | 2017-10-14 | 2017-10-14 | |
PCT/US2018/055733 WO2019075417A1 (en) | 2017-10-14 | 2018-10-12 | CONJUGATES OF MEDICAMENT ANTI-CD71 ACTIVATED ANTIBODIES AND METHODS OF USE |
Publications (1)
Publication Number | Publication Date |
---|---|
MD3691692T2 true MD3691692T2 (ro) | 2021-05-31 |
Family
ID=64110112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MDE20200822T MD3691692T2 (ro) | 2017-10-14 | 2018-10-12 | Conjugaţi medicament anticorp activabili anti-CD71 și metode de utilizare a acestora |
Country Status (34)
Country | Link |
---|---|
US (3) | US20190111150A1 (ro) |
EP (2) | EP3834846A1 (ro) |
JP (2) | JP7374891B2 (ro) |
KR (4) | KR102385495B1 (ro) |
CN (1) | CN111278467A (ro) |
AR (1) | AR115178A1 (ro) |
AU (1) | AU2018346969A1 (ro) |
BR (1) | BR112020007302B1 (ro) |
CA (1) | CA3077730A1 (ro) |
CL (1) | CL2020000977A1 (ro) |
CO (1) | CO2020005685A2 (ro) |
CR (1) | CR20200206A (ro) |
CY (1) | CY1123968T1 (ro) |
DK (1) | DK3691692T3 (ro) |
DO (1) | DOP2023000150A (ro) |
EC (1) | ECSP20025198A (ro) |
ES (1) | ES2864013T3 (ro) |
HR (1) | HRP20210436T8 (ro) |
HU (1) | HUE054037T2 (ro) |
IL (1) | IL273586A (ro) |
LT (1) | LT3691692T (ro) |
MA (1) | MA50752B1 (ro) |
MD (1) | MD3691692T2 (ro) |
MX (1) | MX2020003723A (ro) |
PE (1) | PE20210125A1 (ro) |
PL (1) | PL3691692T3 (ro) |
PT (1) | PT3691692T (ro) |
RS (1) | RS61596B1 (ro) |
RU (2) | RU2771292C2 (ro) |
SG (1) | SG11202003378WA (ro) |
SI (1) | SI3691692T1 (ro) |
TW (2) | TW202330039A (ro) |
UY (1) | UY37931A (ro) |
WO (1) | WO2019075417A1 (ro) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130116404A1 (en) | 2011-11-08 | 2013-05-09 | Case Western Reserve University | Targeted non-invasive imaging probes of egfr expressing cells |
EP3292149B1 (en) * | 2015-05-04 | 2021-12-01 | CytomX Therapeutics, Inc. | Activatable anti-cd71 antibodies, and methods of use thereof |
WO2019183633A1 (en) | 2018-03-23 | 2019-09-26 | Case Western Reserve Univeristy | Psma targeted conjugate compounds and uses thereof |
WO2021205358A1 (en) * | 2020-04-08 | 2021-10-14 | Janssen Biotech, Inc. | Compositions and methods for blood-brain barrier delivery |
US20210317188A1 (en) * | 2020-04-09 | 2021-10-14 | Cytomx Therapeutics, Inc. | Compositions containing activatable antibodies |
WO2023086833A1 (en) | 2021-11-09 | 2023-05-19 | Case Western Reserve University | Psma targeted conjugate compounds and uses thereof |
WO2024026474A1 (en) * | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988001513A1 (en) | 1986-08-28 | 1988-03-10 | Teijin Limited | Cytocidal antibody complex and process for its preparation |
US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
NZ258392A (en) | 1992-11-13 | 1997-09-22 | Idec Pharma Corp | Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona |
EP2535346B1 (en) | 2005-08-31 | 2017-08-02 | The Regents of The University of California | Cellular libraries of peptide sequences (CLiPS) and methods of using the same |
EP3492488A1 (en) | 2007-08-22 | 2019-06-05 | The Regents of The University of California | Activatable binding polypeptides and methods of identification and use thereof |
EP2570137A3 (en) * | 2007-11-07 | 2013-08-21 | Celldex Therapeutics, Inc. | Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) |
EP3543256A1 (en) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
US8765916B2 (en) * | 2009-04-29 | 2014-07-01 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | ERG monoclonal antibodies |
US9309325B2 (en) | 2009-05-07 | 2016-04-12 | The Regents Of The University Of California | Antibodies and methods of use thereof |
SG191977A1 (en) * | 2011-02-01 | 2013-08-30 | Genmab As | Human antibodies and antibody-drug conjugates against cd74 |
HUE054362T2 (hu) * | 2012-01-31 | 2021-09-28 | Sbi Biotech Co Ltd | Foszfolipáz D4 elleni antitest |
EP2882844B1 (en) | 2012-08-10 | 2018-10-03 | Cytomx Therapeutics Inc. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
CN103145847B (zh) * | 2013-02-05 | 2014-05-21 | 浙江大学 | 一种抗cd20抗体-海兔毒素偶联物及其制备方法和应用 |
EP3088419B1 (en) * | 2013-12-25 | 2018-10-10 | Daiichi Sankyo Company, Limited | Anti-trop2 antibody-drug conjugate |
EP3292149B1 (en) * | 2015-05-04 | 2021-12-01 | CytomX Therapeutics, Inc. | Activatable anti-cd71 antibodies, and methods of use thereof |
CN106237341B (zh) * | 2016-07-12 | 2019-07-30 | 浙江大学 | 一种抗体偶联药物及其制备方法和应用 |
-
2018
- 2018-10-12 KR KR1020207013706A patent/KR102385495B1/ko active Application Filing
- 2018-10-12 SI SI201830233T patent/SI3691692T1/sl unknown
- 2018-10-12 TW TW111137633A patent/TW202330039A/zh unknown
- 2018-10-12 MD MDE20200822T patent/MD3691692T2/ro unknown
- 2018-10-12 CA CA3077730A patent/CA3077730A1/en active Pending
- 2018-10-12 PE PE2020000380A patent/PE20210125A1/es unknown
- 2018-10-12 RU RU2020115713A patent/RU2771292C2/ru active
- 2018-10-12 RS RS20210341A patent/RS61596B1/sr unknown
- 2018-10-12 US US16/159,559 patent/US20190111150A1/en not_active Abandoned
- 2018-10-12 EP EP20209320.9A patent/EP3834846A1/en active Pending
- 2018-10-12 WO PCT/US2018/055733 patent/WO2019075417A1/en unknown
- 2018-10-12 HU HUE18797311A patent/HUE054037T2/hu unknown
- 2018-10-12 MX MX2020003723A patent/MX2020003723A/es unknown
- 2018-10-12 EP EP18797311.0A patent/EP3691692B8/en active Active
- 2018-10-12 KR KR1020227044475A patent/KR102529359B1/ko active IP Right Grant
- 2018-10-12 PL PL18797311T patent/PL3691692T3/pl unknown
- 2018-10-12 UY UY0001037931A patent/UY37931A/es unknown
- 2018-10-12 AR ARP180102966A patent/AR115178A1/es unknown
- 2018-10-12 RU RU2022111211A patent/RU2022111211A/ru unknown
- 2018-10-12 AU AU2018346969A patent/AU2018346969A1/en active Pending
- 2018-10-12 CR CR20200206A patent/CR20200206A/es unknown
- 2018-10-12 ES ES18797311T patent/ES2864013T3/es active Active
- 2018-10-12 KR KR1020237014403A patent/KR20230070046A/ko active Application Filing
- 2018-10-12 TW TW107136020A patent/TWI780237B/zh active
- 2018-10-12 HR HRP20210436TT patent/HRP20210436T8/hr unknown
- 2018-10-12 BR BR112020007302-4A patent/BR112020007302B1/pt active IP Right Grant
- 2018-10-12 JP JP2020520804A patent/JP7374891B2/ja active Active
- 2018-10-12 MA MA50752A patent/MA50752B1/fr unknown
- 2018-10-12 KR KR1020227011264A patent/KR20220045088A/ko not_active Application Discontinuation
- 2018-10-12 CN CN201880069577.4A patent/CN111278467A/zh active Pending
- 2018-10-12 DK DK18797311.0T patent/DK3691692T3/da active
- 2018-10-12 PT PT187973110T patent/PT3691692T/pt unknown
- 2018-10-12 SG SG11202003378WA patent/SG11202003378WA/en unknown
- 2018-10-12 LT LTEP18797311.0T patent/LT3691692T/lt unknown
-
2020
- 2020-03-25 IL IL273586A patent/IL273586A/en unknown
- 2020-04-09 CL CL2020000977A patent/CL2020000977A1/es unknown
- 2020-05-07 CO CONC2020/0005685A patent/CO2020005685A2/es unknown
- 2020-05-13 EC ECSENADI202025198A patent/ECSP20025198A/es unknown
- 2020-11-25 US US17/105,402 patent/US20210145978A1/en not_active Abandoned
-
2021
- 2021-03-22 CY CY20211100239T patent/CY1123968T1/el unknown
-
2023
- 2023-05-19 US US18/320,869 patent/US20240115724A1/en active Pending
- 2023-07-27 DO DO2023000150A patent/DOP2023000150A/es unknown
- 2023-10-25 JP JP2023183034A patent/JP2024012366A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MD3691692T2 (ro) | Conjugaţi medicament anticorp activabili anti-CD71 și metode de utilizare a acestora | |
CY1125011T1 (el) | Ενεργοποιουμενα αντισωματα enanti-cd71 και μεθοδοι χρησης αυτων | |
CL2018001646A1 (es) | Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma. (divisional solicitud 201602105) | |
CY1123858T1 (el) | Συζευγματα αντισωματος enanti-cmet δραστικης ουσιας και μεθοδοι για τη χρηση αυτων | |
MX2021005116A (es) | Anticuerpos activables anti-cd166 y metodos de uso de estos. | |
MA38396A1 (fr) | Anticorps medicamenteux conjugues et leurs compositions pharmaceutiques pour traiter un cancer positif a ckit | |
MX2022014125A (es) | Anticuerpos y conjugados de los mismos. | |
EA201691650A1 (ru) | Гидрофильные конъюгаты антитело-лекарственное средство | |
EA201691023A1 (ru) | Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством | |
CU20170169A7 (es) | Anticuerpos de factor xi | |
CR20140585A (es) | Proteinas de union a antigeno st2 | |
EA201790334A1 (ru) | Конъюгаты анти-cdh6 антитела с лекарственным средством | |
WO2014144763A3 (en) | High affinity anti-gd2 antibodies | |
WO2014163714A3 (en) | Antibody drug conjugates | |
WO2015164392A3 (en) | Novel antii-rnf43 antibodies and methods of use | |
EA201792300A1 (ru) | Комбинации иммуноконъюгата к cd37 и антитела к cd20 | |
MA52238A (fr) | Conjugués de médicament d'agents de liaison monoclonaux cmet, et utilisations associées | |
EA201892068A1 (ru) | Конъюгаты napi2b-нацеленное антитело-лекарственное средство и способы их применения | |
TWD182393S (zh) | 拋棄式尿布 | |
TWD182394S (zh) | 拋棄式尿布 | |
TWD182392S (zh) | 拋棄式尿布 | |
TWD182395S (zh) | 拋棄式尿布 | |
MY193448A (en) | Anti-cd166 antibodies, and activatable anti-cd166 antibodies, and methods of use thereof | |
PL411858A1 (pl) | Immunoglobuliny do aglutynacji ludzkich erytrocytów, sposób ich otrzymywania oraz zastosowania | |
TH181126A (th) | Pd-1 แอนติบอดี ชิ้นส่วนที่จับกับแอนติเจนของแอนติบอดีนั้น และการใช้แอนติบอดีนั้นทางการแพทย์ |